Peptide · Inhibitor of beta-catenin (CTNNB1) · developed by Parabilis Medicines
Zolucatetide (FOG-001) is a conformationally stabilized alpha-helical polypeptide that penetrates cells and binds beta-catenin, preventing its interaction with the transcription factor TCF. This blocks transcription of Wnt target genes. It is studied in colorectal, prostate, endometrial and hepatocellular cancers, desmoid tumors and other solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05919264 | Phase 1/2 | Cancer | Recruiting | PBLS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Adamantinomatous CraniopharyngiomaCancerColorectal CancerDesmoidEndometrial CarcinomaFamilial Adenomatous Polyposis (FAP)HCCLocally Advanced Solid TumorMetastatic CancerMetastatic Castration-resistant Prostate CancerMicrosatellite Instability-High Colorectal CancerMicrosatellite Stable Colorectal CancerProstate CancerSolid Tumor
Updated Oct 25, 2026. Something wrong or missing? Report it on the PBLS page.
See PBLS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PBLS catalysts and pipeline →